[HTML][HTML] Programmed death ligand 1 signals in cancer cells
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …
[HTML][HTML] Interferon-γ: teammate or opponent in the tumour microenvironment?
AM Gocher, CJ Workman, DAA Vignali - Nature Reviews Immunology, 2022 - nature.com
Cancer immunotherapy offers substantive benefit to patients with various tumour types, in
some cases leading to complete tumour clearance. However, many patients do not respond …
some cases leading to complete tumour clearance. However, many patients do not respond …
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
J Zhang, Y Hu, J Yang, W Li, M Zhang, Q Wang… - Nature, 2022 - nature.com
Recently, chimeric antigen receptor (CAR)-T cell therapy has shown great promise in
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …
Emerging phagocytosis checkpoints in cancer immunotherapy
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
Revisiting the PD-1 pathway
Programmed Death-1 (PD-1; CD279) is an inhibitory receptor induced in activated T cells.
PD-1 engagement by its ligands, PD-L1 and PD-L2, maintains peripheral tolerance but also …
PD-1 engagement by its ligands, PD-L1 and PD-L2, maintains peripheral tolerance but also …
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous
success treating B cell malignancies; however, some patients fail to respond due to poor …
success treating B cell malignancies; however, some patients fail to respond due to poor …
Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment
A single biomarker is not adequate to identify patients with gastric cancer (GC) who have the
potential to benefit from anti-PD-1/PD-L1 therapy, presumably owing to the complexity of the …
potential to benefit from anti-PD-1/PD-L1 therapy, presumably owing to the complexity of the …
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
JW Kjeldsen, CL Lorentzen, E Martinenaite… - Nature medicine, 2021 - nature.com
Abstract Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for
metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We …
metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We …
Immunogenic PANoptosis‐Initiated Cancer Sono‐Immune Reediting Nanotherapy by Iteratively Boosting Cancer Immunity Cycle
L Zhou, J Lyu, F Liu, Y Su, L Feng… - Advanced …, 2024 - Wiley Online Library
The cancer‐immune cycle conceptualized the mechanisms of driving T cell responses to
tumors, but w as limited by immunological ignorance elicited by tumor inherent …
tumors, but w as limited by immunological ignorance elicited by tumor inherent …
The immune microenvironment in pancreatic cancer
M Huber, CU Brehm, TM Gress, M Buchholz… - International journal of …, 2020 - mdpi.com
The biology of solid tumors is strongly determined by the interactions of cancer cells with
their surrounding microenvironment. In this regard, pancreatic cancer (pancreatic ductal …
their surrounding microenvironment. In this regard, pancreatic cancer (pancreatic ductal …